Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease
Yannick Allanore, Dinesh Khanna, Vanessa M. Smith, Martin Aringer et autres
OBJECTIVES: To investigate the course of interstitial lung disease (ILD) and the effects of nintedanib in patients with limited cutaneous systemic sclerosis (lcSSc). METHODS: In the SENSCIS trial, patients with SSc-ILD were randomized to receive nintedanib or placebo. Patients who completed the …
fr, us, be, de, no, jp, cn, il, gb (code pays fourni par la source)